)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sirnaomics (2257) investor relations material
Sirnaomics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary29 Aug, 2025
Executive summary
Clinical-stage biopharma focused on siRNA therapeutics, leveraging proprietary PNP and GalAhead delivery platforms for a diversified pipeline in oncology, fibrotic diseases, aesthetics, and metabolic disorders.
Lead candidate STP705 prioritized for isSCC pivotal trials after favorable phase II results; BCC and other indications remain in pipeline.
STP707 in phase I for multiple solid tumors, showing good safety and efficacy, especially in pancreatic cancer; further development contingent on 2025 trial data.
STP122G, a GalAhead-based anticoagulant, progressing through phase I with positive safety data; completion expected in 2026.
Strategic restructuring, cost optimization, and leadership changes implemented to enhance operational efficiency and financial sustainability.
Financial highlights
No revenue from product sales for the six months ended June 30, 2025; other income decreased 87% to US$0.1 million.
Net loss narrowed to US$3.4 million from US$43.5 million year-over-year, mainly due to reduced R&D and administrative expenses and lower fair value losses.
Administrative expenses dropped 75% to US$2.6 million; R&D expenses down 79% to US$3.0 million.
Cash and cash equivalents at June 30, 2025 were US$6.9 million, down from US$11.8 million at year-end 2024.
Net cash used in operating activities decreased 68% to US$4.9 million.
Outlook and guidance
Focus remains on advancing STP705 and STP122G, with STP705 targeting NDA submission as early as 2027, contingent on positive clinical data and regulatory approval.
Additional financing, strategic partnerships, and potential divestment of non-core assets actively pursued to extend financial runway and accelerate pipeline development.
Continued cost optimization and resource reallocation to high-value programs.
STP705: Rationale for isSCC prioritization
Detail key cost savings from restructuring efforts
RNAimmune: Update on external financing strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sirnaomics earnings date
H2 202526 Mar, 2026
Next Sirnaomics earnings date
H2 202526 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sirnaomics Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company specializes in developing RNA-based drugs for the treatment of diseases in areas such as oncology, fibrosis, and other serious conditions. Its platform integrates proprietary delivery technologies designed to enhance the targeting and effectiveness of RNAi-based treatments. Sirnaomics Ltd conducts research, clinical development, and regulatory activities as part of its product advancement strategy. The company is headquartered in Suzhou, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage